MOH
- Status: likely_approved
Ditropan Xl (OXYBUTYNIN) regulatory status in Israel.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
Hisamitsu Pharmaceutical Co., Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.